Spots Global Cancer Trial Database for Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Official Title: Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Study ID: NCT02691793
Conditions
Interventions
Study Description
Brief Summary: This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.
Detailed Description:
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
